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Abstract We have isolated a posttranslationally modified form
of peptide YY (PYY) from porcine intestine and shown by
MALDI-TOF and electrospray tandem mass spectrometry that
it is phosphorylated at Ser13. Phospho-PYY exhibits high
affinity for binding to neuropeptide Y (NPY) receptors Y1, Y2
and Y5. The IC50 values with the Y1, Y2, and Y5 receptor
subtypes were for NPY 2.4, 3.1, and 3.3 nM, for PYY 2.3, 0.94,
and 3.2 nM, and for phospho-PYY 4.6, 2.2, and 5.5 nM,
respectively. Phospho-PYY potently inhibits forskolin-stimulated
cAMP accumulation in SK-N-MC cells with an IC50 value of 0.5
nM compared to 0.15 nM for non-phosphorylated PYY. The
finding of phosphorylation of PYY is unusual among hormonal
peptides, and emphasizes the importance of direct protein
analysis of gene products. ß 2001 Federation of European Bio-
chemical Societies. Published by Elsevier Science B.V. All
rights reserved.
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1. Introduction
Peptide YY (PYY) is a 36 residue peptide originally isolated
from porcine upper small intestine using a chemical method to
detect the C-terminal Tyr-amide structure [1,2]. PYY, pancre-
atic polypeptide (PP) [3], and neuropeptide Y (NPY) [4] are
structurally similar and form a peptide family. However, they
are expressed in di¡erent tissues and have distinct functions
[5,6]. While PYY and PP are mainly found in gastrointestinal
mucosa and pancreas and are involved in the control of di-
gestive functions, NPY is the most abundant neuropeptide
present in the nervous systems [7,8]. PYY is present in the
endocrine cells of both the intestine and the pancreas (A-cells)
[9]. PYY mRNA is also expressed in a few neuronal cell
populations of the rat [10,11], and PYY-like immunoreactivity
has been observed in gut neurons of several mammals [12].
PYY is released in response to meals and inhibits gastric and
pancreatic secretion as well as gastric and intestinal mobility
[5].
Several receptors have been identi¢ed that bind all three
peptides, but with di¡erent a⁄nities [8,13^15]. The receptors
belong to the large family of G protein-coupled receptors and
are denoted as Y receptor subtypes (Y1, Y2, Y4, Y5, y6).
PYY and NPY bind with almost equal a⁄nity to Y1 and
Y2 receptors, but PP has signi¢cantly lower a⁄nity towards
these. The Y5 receptor is believed to play a role in orexigenic
properties of NPY [16].
In the present study we have isolated a novel form of PYY.
The new form is phosphorylated at Ser13, de¢ning a class of
gastrointestinal peptide hormones conjugated with a phos-
phate group.
2. Materials and methods
2.1. Puri¢cation of phospho-PYY
A concentrate of thermostable intestinal peptides (CTIP) was pre-
pared from porcine intestines, and an aqueous solution of CTIP was
fractionated with ethanol [17], and a fraction precipitating at pH
7.2 þ 0.1 prepared as described [18].
The ¢rst HPLC puri¢cation step was performed under the same
conditions as reported earlier [18], but the puri¢cation now followed
measurements of cAMP production in SK-N-MC cells. An active
fraction eluting between 150 and 160 ml was collected and used in
the subsequent puri¢cation.
The second cation exchange HPLC step was carried out using the
same column at a lower pH. The column was equilibrated with 20
mM Na-phosphate (pH 2.5) containing 20% acetonitrile (bu¡er A),
the sample was diluted 10 times with water, the pH adjusted to 2.5,
and loaded onto the column. The peptides were eluted with a gradient
of 9^23.5% bu¡er B, which consisted of the equilibration bu¡er con-
taining 2 M NaCl. The elution was completed in 30 column volumes
(CV) at a £ow rate of 20 ml/min.
The third step was a reverse phase (RP) HPLC on a YMC
ODS-AP, 10U100 mm column (5 Wm, 300 Aî ). Eluent A was 0.1%
tri£uoroacetic acid (TFA)/water, and eluent B was 0.1% TFA/95%
acetonitrile/water, the gradient was 20^40% B in 30 CV. The peak
fraction with cAMP producing activity was further puri¢ed through
another step of RP-HPLC.
The ¢nal puri¢cation of phospho-PYY by RP-HPLC was carried
out on a WRPC C2/C18 column (4.6U100 mm, Amersham Pharmacia
Biotech) (Fig. 1) eluted with the solvent system consisting of eluent A,
0.1% TFA/water, and eluent B, 0.1% TFA/95% acetonitrile/water. A
gradient of 30^45% B in 15 CV was used. The peak fraction was
analyzed.
2.2. Sequence analysis
Edman degradation was carried out using a Procise HT instrument
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(Applied Biosystems). Samples were applied to Biobrene-treated glass
¢ber ¢lter discs.
2.3. Tryptic cleavage and desalting
Trypsin cleavage was carried out in 0.1 M ammonium bicarbonate
at 37‡C using modi¢ed enzyme from Promega (0.2 Wg). The peptides
in the digest were either separated by RP-HPLC or desalted on a
Poros R3 resin (Perseptive Biosystems), where the peptides were
eluted with 60% acetonitrile containing 1% acetic acid.
2.4. Mass spectrometry
Mass spectrometric data were acquired on a hybrid quadrupole
time-of-£ight (Q-TOF) mass spectrometer (MS) (Micromass, Man-
chester, UK), a Voyager DE Pro (Perseptive Biosystems, Framing-
ham, MA, USA), and a Finnigan Lasermat 2000 (Thermo Bio-
analysis, UK) as described [19,20].
2.5. Receptor binding assay
Cells used in the binding experiments with NPY receptor subtypes
were SK-N-MC for the NPY1, KAN-Ts for the NPY2, and HEK293
transfected with human NPY5 cDNA for the NPY5 receptor. Cells
were grown to con£uence on 150 cm2 tissue culture plates, washed
with phosphate-bu¡ered saline (PBS), and scraped into 50 ml tubes.
After centrifugation, the supernatant was aspirated, and the pellets
frozen and stored at 380‡C. Thawed pellets were homogenized with a
tissue grinder for 8 s in 20 mM Tris^HCl, 2 mM EDTA. The homog-
enate was centrifuged at 800Ug for 5 min and the collected super-
natant recentrifuged at 25 000Ug for 25 min. The resulting pellet was
resuspended in binding bu¡er (20 mM HEPES, 120 mM NaCl, 0.22
mM KH2PO4, 1.3 mM CaCl2, 0.8 mM MgSO4). Membranes were
incubated with [125I]PYY (300 pM) in the presence or absence of
test compound for 1 h at room temperature. The reaction was stopped
by centrifugation and subsequent removal of the supernatant. The
pellets were washed once with PBS and the radioactivity was counted
in a Packard Cobra gamma counter. Speci¢c binding to the NPY
receptor subtypes was determined by radioactivity that was bound
in the presence of 300 nM NPY.
2.6. cAMP accumulation assay
SK-N-MC human neuroblastoma cells that express NPY1 receptors
were plated in 96 well plates. When con£uent, DMEM^F12 medium
was replaced with 100 Wl/well fresh medium supplemented with 2 mM
isobutylmethylxanthine. After 20 min, cells were exposed to PYY or
phospho-PYY at various concentrations. After 10 min, forskolin was
added to a ¢nal concentration of 1 WM. After an additional 20 min,
0.2 vol 0.5 N HCl was added to each well. Cells were kept frozen
overnight, thawed, and a 20 Wl aliquot of the medium was transferred
to a cAMP Flashplate (NEN, Boston, MA, USA). [125I]cAMP was
added and the subsequent radioimmunoassay (RIA) was measured
using a Packard Topcount microplate reader after overnight incuba-
tion at 4‡C.
2.7. Assay for insulin release from pancreatic islets
The e¡ect of peptide fractions on glucose-induced insulin release
was monitored in a system of isolated rat pancreatic islets [21]. After
incubation, samples of the medium were analyzed with RIA of insulin
[21].
3. Results and discussion
3.1. Puri¢cation
Fractions from pig intestinal extracts were screened for pep-
tides which increased cAMP production in SK-N-MC cells.
Further puri¢cation separated phospho-PYY from these and
other contaminating peptides (Fig. 1), and the pure fraction
was subjected to structural analysis.
3.2. Structural analysis
The puri¢ed peptide was analyzed by Edman degradation
that revealed a sequence corresponding to porcine PYY.
The molecular mass of the peptide was determined by ma-
trix-assisted laser desorption ionization (MALDI)-TOF and
electrospray (ES) mass spectrometries (MS), and a monoiso-
topic mass value of 4318.3 Da was obtained. The result in-
dicates that the peptide has an about 80 Da higher mass than
predicted from the amino acid sequence of PYY (4238.13 Da)
suggesting that the peptide is phosphorylated or sulfated.
To identify the modi¢cation and its position, the puri¢ed
peptide was digested with trypsin. Analysis of the resulting
peptides by MALDI-TOF MS indicated that the modi¢ed
residue is in the N-terminal tryptic fragment, PYY (residues
1^19; YPAKPEAPGEDASPEELSR). This fragment was in-
vestigated using ES-MS/MS. The triply charged form of the
peptide (m/z 708.31) was subjected to collision-induced disso-
ciation (CID) in the positive ion mode. Series of y- and b-type
ions were detected and the y-ions following y7 (at m/z 897.40)
were found to be shifted (Fig. 2). Interpretation of the prod-
uct ion spectrum showed that the 80 Da modi¢cation, ^HPO3
(79.9663 Da) or ^SO3 (79.9568 Da) was located to Ser13. To
further ascertain the identity of the modi¢cation the peptide
was analyzed in the negative ion mode. The doubly deproto-
nated parent ion (m/z 1059.95) was subjected to CID. The
product ion spectrum showed an intense peak at 78.9664,
characteristic of PO33 , indicating the presence of a phosphate
group in the peptide. From these results we conclude that the
native PYY is phosphorylated at Ser13.
Ser13-phospho-PYY was synthesized and analyzed by
ES-MS/MS. The mass spectra of the synthetic peptide were
identical to those of the peptides isolated from the intestinal
material, con¢rming the structure.
Phosphorylation in PYY is probably catalyzed by a protein
kinase, most likely casein kinase [22], which recognizes the
sequence ^Ser/Thr-X-Glu/Asp^, where X is any amino acid.
Indeed, PYY contains such a consensus sequence near Ser13,
where X = Pro.
The peptides in the PP/NPY/PYY family are highly con-
served among di¡erent animal species. Comparison of these
three porcine peptides with PYY from several other species
indicates that within PYY, the serine residue at position 13 is
conserved throughout all characterized mammalian species
(Fig. 3). It is therefore probable that phosphorylation of
PYY at Ser13 may also occur in other species, including hu-
mans. However, the other two family members, PP and NPY,
Fig. 1. Final puri¢cation of phospho-PYY from porcine intestine by
RP-HPLC. Column, WRPC C2/C18 (4.6U100 mm); mobile phase,
0.1% TFA/water (eluent A), 0.1% TFA/95% acetonitrile/water (elu-
ent B); gradient 30^45% eluent B in 15 column volumes. The frac-
tion marked with the arrow was analyzed.
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are di¡erent at just this position. Peptide PP has Thr at
position 13. Although Thr may also be phosphorylated in
biological systems, this often appears less decisive, and it is
therefore possible that the PP molecule is quite di¡erent in
sensitivity to phosphorylation. More di¡erently, the NPY se-
quence has a Pro at position 13, which excludes the existence
of an NPY phosphopeptide involving that position.
3.3. Biological activity
Phospho-PYY was assayed in SK-N-MC cells for cAMP
production and for inhibition of forskolin-stimulated cAMP
production (Fig. 4). We found that PYY and phospho-PYY
had no e¡ect on basal cAMP production in SK-N-MC cells
up to micromolar concentrations. Phospho-PYY strongly in-
hibited forskolin-stimulated cAMP production in these cells
similarly to PYY. The IC50 value for phospho-PYY was 0.5
nM, and for non-phosphorylated PYY it was 0.15 nM. We
also tested the e¡ects of phospho-PYY on several NPY re-
ceptor subtypes and found that it had high a⁄nity for Y1, Y2,
and Y5 receptors as determined by displacement of [125I]PYY.
The IC50 values with the Y1, Y2, and Y5 receptor subtypes
were for NPY 2.4, 3.1, and 3.3 nM, for PYY 2.3, 0.94, and 3.2
nM, and for phospho-PYY 4.6, 2.2, and 5.5 nM, respectively.
The e¡ect of phospho-PYY on insulin secretion was tested
in isolated pancreatic islets from rats at di¡erent concentra-
tions and was compared to that of unmodi¢ed PYY. No e¡ect
was observed either with synthetic unmodi¢ed PYY or with
synthetic phospho-PYY. Similarly, PYY was without e¡ect on
basal and glucose-induced insulin release when infused in fed
anesthetized rats [23].
Phosphorylation is a general regulatory mechanism that
occurs in cellular proteins. However, phosphorylation of bio-
active peptides or their precursors has been described earlier
only in a few cases, such as ACTH, proenkephalin A,
chromogranin A, and a few others [24^28]. Proenkephalin
A-derived peptides have been shown to acquire antibacterial
properties upon phosphorylation [29].
The exact amount of phosphorylated PYY could not be
determined from mass spectrometry but phospho-PYY is a
minor form, compared to its non-phosphorylated counterpart.
The ¢nding of phospho-PYY is unusual, since it represents
phosphorylation in a secreted hormonal peptide. Given the
slightly lower receptor binding and inhibitory activities of
cAMP production of the phosphorylated PYY than of the
non-phosphorylated peptide, phosphorylation is not a mech-
anism to switch the product on or o¡, but could participate in
¢ne regulation of PYY activity. Moreover, the peptide may
speci¢cally recognize a yet undiscovered receptor subtype, or
be involved in a yet unknown biological function for this
peptide. It is also possible that phosphorylation may alter
the stability of the peptide in its biological environment.
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Fig. 4. Interaction of phospho-PYY with NPY subtypes. E¡ect of
PYY (triangles) and phospho-PYY (circles) on basal (empty sym-
bols) and forskolin-stimulated cAMP accumulation (¢lled symbols)
in SK-N-MC cells. The cells were incubated with peptides in the
presence and absence of forskolin and the accumulated cAMP was
measured using the Flashplate technique.
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